NovoBioBank now stands ready to help researchers harness the true power and value in their biobank, fueling contemporary investigation – from basic research to clinical trials – through the better management of well-characterized biospecimens.
(PRWEB) September 20, 2012
NovoPath, Inc., a leader in Anatomic Pathology Best-of-Breed Software Solutions, announces the addition of NovoBioBank – a breakthrough in biospecimen banking. NovoBioBank operates as either a stand-alone or integrated system, seamlessly interfacing with Laboratory Information Systems (LIS) and Clinical Research Information Systems (CRIS).
A well-administered biobank is critical for conducting high-quality sophisticated biological research, and NovoBioBank provides all necessary tools. This fully customizable intuitive software solution, based on user-designed specs, supports effortless, scalable collaboration between multiple sites. NovoBioBank is a robust, flexible module that enables collection of pertinent specimen data, extensive search parameters and on-the-spot information – including order status, shipping, billing and maintenance reports.
NovoBioBank supports the capture, standardization and organization of wide-ranging relevant data – both patient/donor and biospecimen oriented – providing secure access to well-annotated biospecimens, while maintaining confirmed chain of custody. Data is managed and tracked through all phases of the complete biospecimen life-cycle – from informed consent, through annotation, collection, processing, QA, inventory/archival control, distribution fulfillment, and finally, to disposal. Full search capacity of operator-defined annotation and query criteria cover all data parameters from patient/donor demographics through to specimen molecular analysis – and everything in between.
Tim Marshall, NovoPath’s Vice President of Strategic Account Development, stated, “Today, biospecimens are being tapped to support research geared toward understanding the mechanisms of disease, identifying novel drug targets, developing clinically relevant biomarkers and an expansive range of cutting-edge research. NovoBioBank now stands ready to help researchers harness the true power and value in their biobank, fueling contemporary investigation – from basic research to clinical trials – through the better management of well-characterized biospecimens.”
About NovoPath, Inc.:
NovoPath, Inc. develops and markets software solutions for the Anatomic Pathology Laboratory market segment that includes local, regional, national, in-house laboratories as well as community and university teaching hospitals and medical centers. Since the release of its flagship product in 1999, NovoPath, Inc. has focused exclusively on Anatomic Pathology. NovoPath's mission is to provide unique and unparalleled solutions and services to all aspects of the Anatomic Pathology sector in a way that improves workflow, reduces the probability of human error, ensures results accuracy for greater patient safety, protects patient confidentiality, and above all, produces more precise and informative diagnostic outcomes. More information is available at http://www.NovoPath.com.